AstraZeneca, Merck get Lynparza ok for pancreatic cancer

Dec. 30, 2019

AstraZeneca and Merck’s ovarian cancer drug, Lynparza, has received U.S. FDA approval for the treatment of advanced pancreatic cancer.

The PARP inhibitor is now the only approved drug in biomarker-selected patients with advanced pancreatic cancer.

In a pivotal Phase III trial, Lynparza reduced the risk of disease progression or death by 47% in patients whose disease had not progressed on at least 16 weeks of a 1st-line platinum-based chemotherapy regimen.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. It is approved in the U.S., the EU, Japan, China and several other countries as 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy. It is also approved in 44 countries, including the US and Japan, for BRCA-mutated, HER2-negative, metastatic breast cancer.

Read the press release